Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
By Chris Wack Soleno Therapeutics said that the Food and Drug Administration has granted Breakthrough Therapy Designation for diazoxide choline extended-release tablets for the treatment.
Osaka, Japan and Waltham, Massachusetts, April 30, 2024 - ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. today announced that on April 29, 2024 , ONO and Deciphera entered.